Substitute for form 1449/PTO				Complete if Known	
FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE				Application Number	10/587,714
				371(c) Date	June 4, 2007
				First Named Inventor	Jane K. Relton
STATEMENT BY APPLICANT (Use as many sheets as necessary)			ICANT	Art Unit	1646
			y)	Examiner Name	WEGERT, Sandra L.
Sheet	1	of 1		Attorney Docket Number	2681.0450001/EJH/JBF
			U.S. PATE	NT DOCUMENTS	
-	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Examiner initials*	No.1	Number-Kind Code 2 (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appe

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
			-		
			ļ		

FOREIGN PATENT DOCUMENTS								
Examiner initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
	FP16	Code ⁵ (if known) WO 03/035687 A1	05-01-2003	Novartis Pharma GmbH				

1316878_1.DOC

Examiner	Date Considered	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant "Applicant's unique citation designation number (optional)." See Kinds Codes of USPTO Patent Documents at two uspits og ow MPEP 901.04. * Instru Office that issued the document, by the two-lender, of WIPO Standard ST.3.." For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO .					
FIFTH S INFORM STATEM	UPPLE IATION MENT B' Use as many	MENT. DISCL Y APP	AL LOSURE PLICANT necessary)		
Sheet	1	of	1		

Complete if Known				
Application Number	10/587,714			
371(c) Date	June 4, 2007			
First Named Inventor	Jane K. Relton			
Art Unit	1646			
Examiner Name	WEGERT, Sandra L.			
Attorney Docket Number	2681.0450001/EJH/JBF			

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²			
//	NPL44	Connor, B., et al., "Adenoviral Vector-Mediated Delivery of Glial Cell Line- Derived Neurotrophic Factor Provides Neuroprotection in the Aged Parkinsonian Rat," Clin. Exp. Pharma. Physiol. 28:896-900, Blackwell Publishing Asia Pty Ltd. (2001)				
	NPL45	MacDermid, VE, et al., "Plasticity of descending dorsal root projections after partial spinal cord deafferentation and the use of anti-inhibitory strategies to myelin inhibitory proteins," Neuroscience 2003 Abstract No. 42.13, Society for Neuroscience (2003)				
	NPL46	Muramatsu, S., et al., "Gene therapy of Parkinson's disease: AAV vectors for delivery of therapeutic genes into mammalian brains," Inflammation and Regeneration 23(4):218-222 (2003)				
	NPL47	Murray, T.K., et al., "LY503430, a Novel c-Amino-3-hydroxy-5-methylisoxazole- 4-propionic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson's Disease," J. Pharma. Exp. Therapeutics 306:752-62, American Society for Pharmacology and Experimental Therapeutics (2003)				

1316885_1.DOC

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MFEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant is unique detainor designation number (options)**. Applicant is unique extation designation number (options)**. Applicant is unique extation designation is attached.